Exploration of Risk Factors of the Onset of Antibiotics-induced Acute Kidney Injury and Its Transfer to Chronic Kidney Disease Using the Medical Information Database
-
- Ieda Masaya
- Department of Regulatory Science, Graduate School of Pharmaceutical Sciences, Nagoya City University
-
- Kuroda Yuka
- Department of Regulatory Science, Graduate School of Pharmaceutical Sciences, Nagoya City University
-
- Matsumoto Takahiro
- Department of Regulatory Science, Graduate School of Pharmaceutical Sciences, Nagoya City University
-
- Yamashita Ayaka
- Department of Regulatory Science, Graduate School of Pharmaceutical Sciences, Nagoya City University
-
- Watanabe Takashi
- Department of Regulatory Science, Graduate School of Pharmaceutical Sciences, Nagoya City University
-
- Hori Katsuhito
- Department of Hospital Pharmacy, Hamamatsu University School of Medicine
-
- Kimura Michio
- Department of Health Informatics, Faculty of Health and Welfare Services Administration, Kawasaki University of Medical Welfare
-
- Kawakami Junichi
- Department of Hospital Pharmacy, Hamamatsu University School of Medicine
-
- Tohkin Masahiro
- Department of Regulatory Science, Graduate School of Pharmaceutical Sciences, Nagoya City University
Bibliographic Information
- Other Title
-
- 医療情報データベースを活用した抗菌薬による薬剤性急性腎障害の発症及び慢性腎臓病へ移行するリスク因子の探索
Description
<p>Drug-induced acute kidney injury (AKI) is a serious adverse drug reaction, which results in a significant decline in renal function and is known to progress to chronic kidney disease (CKD). Therefore, appropriate drug therapy is important to avoid the risk of drug-induced AKI and CKD, which are serious concerns in clinical practice. In this study, using the medical information database of Hamamatsu University Hospital, we investigated the risk factors that accelerate the onset of drug-induced AKI or its progression to CKD in patients who received aminoglycoside antibiotics (AGs) or glycopeptide antibiotics (GPs), which are strongly associated with drug-induced AKI and CKD. We performed logistic regression analysis using patients’ background, laboratory test results, and concomitant drug use, among other such factors as explanatory variables and drug-induced AKI or CKD onset as objective variables to explore the risk factors for drug-induced AKI and CKD. Our results showed that co-administration of amphotericin B, piperacillin-tazobactam and other AGs and GPs, increased serum creatinine (Scr) and chloride concentrations, serum lactate dehydrogenase activity, and decreased serum albumin concentration were risk factors for drug-induced AKI onset. Moreover, a reduced blood urea nitrogen : Scr ratio at drug-induced AKI onset served as a risk factor for CKD. These results suggest that careful monitoring of the aforementioned factors is important to ensure appropriate usage of these drugs in patients treated with AGs and GPs.</p>
Journal
-
- YAKUGAKU ZASSHI
-
YAKUGAKU ZASSHI 144 (4), 447-462, 2024-04-01
The Pharmaceutical Society of Japan